NASDAQ:IDXX - IDEXX Laboratories Stock Price, Forecast & News

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories announced that its Board of Directors has authorized a share repurchase plan on Wednesday, February 12th 2020, which allows the company to buyback 5,000,000 shares, according to EventVestor. This buyback authorization allows the company to buy shares of its stock through open market purchases. Shares buyback plans are often an indication that the company's leadership believes its shares are undervalued.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its earnings results on Friday, January, 31st. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.91 by $0.13. The firm had revenue of $605.50 million for the quarter, compared to the consensus estimate of $600.60 million. IDEXX Laboratories had a return on equity of 283.27% and a net margin of 17.77%. The company's revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.98 earnings per share. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories issued an update on its FY20 earnings guidance on Friday, January, 31st. The company provided EPS guidance of $5.42-5.58 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.41. The company issued revenue guidance of $2.62-2.66 billion, compared to the consensus revenue estimate of $2.63 billion.

6 brokers have issued twelve-month target prices for IDEXX Laboratories' shares. Their forecasts range from $277.00 to $310.00. On average, they expect IDEXX Laboratories' share price to reach $293.33 in the next twelve months. This suggests a possible upside of 13.1% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

Media headlines about IDXX stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. IDEXX Laboratories earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for IDEXX Laboratories.

IDEXX Laboratories saw a increase in short interest in February. As of February 14th, there was short interest totalling 1,320,000 shares, an increase of 9.1% from the January 30th total of 1,210,000 shares. Based on an average daily trading volume, of 494,600 shares, the days-to-cover ratio is currently 2.7 days. Currently, 1.6% of the company's stock are short sold. View IDEXX Laboratories' Current Options Chain.

Some companies that are related to IDEXX Laboratories include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Steris (STE), Insulet (PODD), Hologic (HOLX) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Paypal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Adobe (ADBE), Mastercard (MA), Intuitive Surgical (ISRG), Home Depot (HD), Micron Technology (MU) and salesforce.com (CRM).

IDEXX Laboratories' stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (4.40%), Bamco Inc. NY (4.39%), Geode Capital Management LLC (1.82%), Blair William & Co. IL (1.80%), Principal Financial Group Inc. (1.39%) and Capital World Investors (1.28%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., Skandinaviska Enskilda Banken AB publ , Bamco Inc. NY, Massachusetts Financial Services Co. MA, MERIAN GLOBAL INVESTORS UK Ltd, MERIAN GLOBAL INVESTORS UK Ltd and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was acquired by a variety of institutional investors in the last quarter, including KBC Group NV, Robeco Institutional Asset Management B.V., Beacon Investment Advisory Services Inc., State Street Corp, Credit Suisse AG, Bank of Montreal Can, Great Diamond Partners LLC and Geode Capital Management LLC. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $259.45.

IDEXX Laboratories has a market capitalization of $22.14 billion and generates $2.41 billion in revenue each year. The company earns $427.72 million in net income (profit) each year or $4.89 on an earnings per share basis. IDEXX Laboratories employs 9,200 workers across the globe.View Additional Information About IDEXX Laboratories.

The official website for IDEXX Laboratories is http://www.idexx.com/.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]